Risk factor
Very high price volatility
Profitability factor
Greatly undervalued vs peers
About
Sutro Biopharma, Inc. operates as clinical stage drug discovery, development, and manufacturing company. It focuses on creating protein therapeutics for cancer and autoimmune disorders through integrated cell-free protein synthesis and site-specific conjugation platform, XpressCF+.The company's product candidates include STRO-001, an antibody-drug conjugate (ADC) directed against the cancer target CD74 for patients with multiple myeloma and...
Company Valuation
Based on key historical and expected multiples, the stock is greatly undervalued relative to its peers.
Target Price
The average target price of STRO is 25 and suggests 157% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell